Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 123
- Registration Number
- NCT00193206
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-11-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00193453
- Locations
- 🇺🇸
Gainsville Hematology Oncology Associates, Gainesville, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193466
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193440
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
- Conditions
- Colon Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00193219
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
🇺🇸Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT00193258
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
- Conditions
- Neoplasms, Unknown Primary
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00193609
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Greenview Regional Hospital, Bowling Green, Kentucky, United States
🇺🇸Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
- Conditions
- Neuroendocrine Carcinoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00193531
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193284
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT00193076
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States